Compare LAC & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | APMD |
|---|---|---|
| Founded | 2023 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2023 | 2026 |
| Metric | LAC | APMD |
|---|---|---|
| Price | $3.01 | $26.71 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.14 | N/A |
| AVG Volume (30 Days) | ★ 9.4M | 380.2K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $20.02 |
| 52 Week High | $10.52 | $35.29 |
| Indicator | LAC | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 48.62 |
| Support Level | $2.90 | $23.98 |
| Resistance Level | $3.58 | $30.34 |
| Average True Range (ATR) | 0.15 | 3.25 |
| MACD | 0.00 | -0.41 |
| Stochastic Oscillator | 5.15 | 9.43 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).